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Objective. To compare local and systemic proﬁles between diﬀerent disease pathologies (pneumonia and encephalitis) induced by
inﬂuenza A virus (IAV).Methods. An IAV pneumonia model was created by intranasal inoculation of C57BL/6 mice with inﬂuenza
A/WSN/33 (H1N1) virus. Lung lavage and blood collection were performed on day 3 after IAV inoculation. Similarly, an IAV
encephalitis mouse model was created by direct intracranial IAV inoculation. Cerebrospinal ﬂuid (CSF) and blood collection
were conducted according to the same schedule. Cytokine/chemokine proﬁles were produced for each collected sample. Then
the data were compared visually using radar charts. Results. Serum cytokine proﬁles were similar in pneumonia and encephalitis
models, but local responses between the bronchoalveolar lavage ﬂuid (BALF) in the pneumonia model and CSF in the
encephalitis model diﬀered. Moreover, to varying degrees, the proﬁles of local cytokines/chemokines diﬀered from those of
serum in both the pneumonia and encephalitis models. Conclusion. Investigating local samples such as BALF and CSF is
important for evaluating local immune responses, providing insight into pathology at the primary loci of infection. Serum data
alone might be insuﬃcient to elucidate local immune responses and might not enable clinicians to devise the most appropriate
treatment strategies.
1. Introduction
Cytokines and chemokines are key factors in the patho-
genesis of inﬂuenza A virus (IAV) infection in human
and animal models. Numerous studies of various IAV
strains have revealed the involvement of various cyto-
kines/chemokines in the pathology of this organism [1].
IAV infection causes various diseases in diﬀerent organs,
ranging from pneumonia [2–7] to encephalitis/encepha-
lopathy [8–11]. To devise appropriate treatment strategies,
the pathological events occurring at the primary loci of
disease must be elucidated. Most reports describe studies
that have used serum to investigate the cytokine/chemokine
proﬁles of IAV-infected patients, especially pneumonia
patients [2–7]. Nevertheless, it remains unclear whether
these serum data correlate with the local immune response
against IAV.
This background has prompted us to characterize the
inﬂammatory mediator response in serum compared with
local samples, that is, bronchoalveolar lavage ﬂuid (BALF)
and cerebrospinal ﬂuid (CSF) in IAV pneumonia and IAV
encephalitis mouse models, respectively. This report presents
evidence that interpreting a serum cytokine/chemokine
proﬁle in terms of a local immune response against IAV
infection can be misleading.
2. Materials and Methods
2.1. Ethics. The Animal Use Committee of the Okayama
University Graduate School of Medicine, Dentistry and
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Pharmaceutical Sciences approved this study (number
OKU-2012628), which was conducted in accordance with
the National Institutes of Health Guidelines.
2.2. Experimental Animals. Eight-week-old male C57BL/6
mice were purchased from Charles River Laboratories Japan
Inc. (Yokohama, Japan). The mice were housed in a speciﬁc
pathogen-free animal facility at 25°C with a 12 hr light/dark
cycle. They were fed a standard diet (Oriental MF; Oriental
Yeast Co. Ltd., Tokyo, Japan).
2.3. Preparation of Viral Inocula. Inﬂuenza A/WSN/33
(H1N1) virus was kindly provided by the Department of
Microbiology, Kawasaki Medical University. This mouse-
adapted H1N1 human IAV strain is not only pneumotropic
after intranasal inoculation; it is also neurovirulent after
inoculation into the CSF [12, 13]. We used this strain
throughout this study. The virus was grown in 10-day-old
embryonated chicken eggs. The virus titre was quantitated
using a plaque assay with Madin-Darby canine kidney cells.
2.4. Experimental Processes. Nine-week-old C57BL/6 mice
were divided into two groups to create a pneumonia
model and an encephalitis model. To create the pneumo-
nia model, the mice were inoculated intranasally with
IAV (5.0× 103 pfu) suspended in 25 μL sterile phosphate-
buﬀered saline (PBS) after being anesthetized with isoﬂur-
ane. Similarly, to create an encephalitis model, IAV was
inoculated directly into the CSF (2.0× 103 pfu) of the mice.
For inoculation of IAV into the CSF, a hole was made in
the skull using a 30-gauge (0.9mm) injection needle. Then
the virus was injected slowly in a volume of 25 μL [14].
These IAV doses were selected because they were 100%
lethal for each type of infection. Moreover, inoculation to
a speciﬁc site did not cause infections at other sites. Control
mice in each model were inoculated with PBS alone. All mice
recovered from the operation. They were examined as
described below. The day of virus inoculation was deﬁned
as day 0. Body weight of mice infected was monitored
for 5 days after inoculation in each model.
Sample collection was performed on day 3 after IAV
inoculation (six mice per group at each time point). For the
pneumonia model, the mice were euthanized humanely;
blood was sampled for cytokine/chemokine measurements.
The left lung hilus was subsequently ligated; the right lung
was lavaged twice with 500 μL cold PBS through a 20-gauge
cannula. The recovered BALF was collected and centrifuged.
Then the supernatant was stored at −80°C before cytokine/
chemokine analysis. The left lung was preserved for histolog-
ical analysis (described below). For the encephalitis model,
the mice were euthanized humanely. Their blood was
sampled. The CSF was collected using the following method.
After exteriorizing the foramen magnum with the neck
anteﬂexed with the operator’s ﬁrst ﬁnger and thumb, the
foramen magnum was punctured with the needle-like
thermoformed MICROCAPS (64mm length, 0.9017mm
O.D., 0.62992mm I.D.; Drummond Scientiﬁc Co., Broomall,
PA, USA); CSF was collected using capillarity. Approxi-
mately 5 μL of CSF was sampled using this method. Blood-
contaminated CSF was removed. Then the collected CSF
was stored at −80°C before cytokine/chemokine analysis.
Subsequently, the brain was excited and preserved for
histological analysis.
Cytokines and chemokines in serum, BALF, and CF
including granulocyte-colony stimulating factor (G-CSF),
interferon-gamma (IFN-γ), interleukin- (IL-) 1β, IL-6, IL-10,
IL-12, IL-13, IL-15, monocyte chemotactic protein- (MCP-)
1, macrophage inﬂammatory protein- (MIP-) 1α, interferon-
gamma-inducible protein- (IP-) 10, and tumor necrosis
factor- (TNF-) α, were measured using a mouse cytokine/
chemokine-magnetic bead panel (Millipore Corp., Billerica,
MA, USA) in a Luminex 100 system (Millipore Corp.).
For the evaluation of viral propagation, the lung and
brain were harvested immediately after inoculation and on
days 1, 3, and 5 after IAV inoculation. The lower half of the
left lung and the right anterior portion of the brain were
excised and soaked in RNAlator for virus quantiﬁcation anal-
ysis. Total RNA was extracted from the preserved specimens
in RNAlator using the RNeasy Plus Mini kit (Qiagen Inc.,
Hilden, Germany). Total RNA was reverse-transcribed to
cDNA using RETROscript (Applied Biosystems, Foster City,
CA, USA) according to the manufacturer’s instructions.
The cDNA was used as a template for PCR (7500 Real-
Time PCR System; Applied Biosystems). The probe and
primers for the analysis of the expression of inﬂuenza
virus type A (M gene) mRNA were the following [15]:
TaqMan probe, 5′-6CCCTCAAAGCCGAGATCGCACAG
AGAC-3′; forward primer, 5′-CGTTCTCTCTATCATCCC
GTCAG-3′; reverse primer, 5′-GGTCTTGTCTTTAGCCA
TTCCATG-3′ [GenBank NC_002016].
The remaining portions of the lung and brain specimens
were frozen in optimal cutting temperature compound and
were subsequently sliced into 4-μm-thick sections using a
cryostat. The cryosections were blocked by acetone. Fluores-
cent immunohistochemical analysis for IAV nucleoprotein
was performed using the anti-inﬂuenza A virus nucleopro-
tein antibody (Abcam plc., Cambridge, UK) according to
the manufacturer’s instructions.
2.5. Statistical Analysis. Comparisons were performed using
the Mann–Whitney U test with software (Prism 6.0;
GraphPad Software Inc., San Diego, CA, USA). A p value of
p < 0 05 was considered statistically signiﬁcant.
3. Results
3.1. Conﬁrmation of Infection at Respective Sites. Fluorescent
immunostaining of the lung obtained from the pneumo-
nia model revealed IAV in the bronchial epithelium
(Figure 1(a)). In the encephalitis model, the viral antigen
was detected in the third and fourth brain ventricles and
in the brain cortex (Figure 1(b)). No viral antigen was
detected in the brain in the pneumonia model or in the
lung in the encephalitis model (data not shown).
Virus quantiﬁcation in the infected organs using
real-time RT-PCR demonstrated a gradual increase from
102 copies/mg tissue to 106 copies/mg tissue for the ﬁrst three
days, with virus numbers then reaching a plateau in each
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group (Figures 1(c) and 1(d)). No viral RNA was detected in
the brain in the pneumonia group or in the lung in the
encephalitis group.
3.2. Measurement of Cytokines and Chemokines. Serum
cytokines and chemokines were measured to assess the
systemic immune response against IAV infection in each
model. All 12 cytokines/chemokines investigated were
increased signiﬁcantly in the IAV pneumonia model
compared with the control (Figure 2(a)), whereas all factors
other than IL-1β increased signiﬁcantly in the IAV encepha-
litis model compared with the control (Figure 2(b)). The
cytokines and chemokines were then measured in the BALF
and CSF in the pneumonia and encephalitis models,
respectively, to observe local inﬂammatory responses at
the site of infection. All 12 factors were increased signiﬁ-
cantly in both models compared with the controls
(Figures 2(c) and 2(d)).
3.3. Comparison of Cytokine/Chemokine Proﬁles. Because
many cytokines and chemokines are involved in the
pathogenesis of disease induced by IAV, we inferred that
understanding the overall cytokine/chemokine proﬁles is
beneﬁcial for understanding disease pathology. Conse-
quently, we attempted to represent and compare each
cytokine/chemokine proﬁle with a radar chart and evaluate
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Figure 1: Immunoﬂuorescent staining and virus propagation at each infected site. Immunoﬂuorescent staining of the lung (a) and the brain
(b) 5 days postinfection detected inﬂuenza A virus (IAV), in the bronchial epithelium and the cerebral cortex, respectively. Images are
representative of 4 mice per model. IAV propagation was detected both in the lung (c) and in the brain (d) by reverse transcription
polymerase chain reaction (n = 3 mice for day 0, n = 5–7 mice for days 1, 3, and 5 per group). Body weight of mice infected with
intranasal IAV (e) and intracranial IAV (f) was monitored for 5 days after inoculation (n = 15 mice for days 0 and 1, n = 10 mice for days
2 and 3, and n = 5 mice for days 4 and 5 per group). Mice in the pneumonia group lost about 20% of their body weight, whereas mice in
the encephalitis group showed about 30% weight loss. All data represent the mean± SEM values.
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the correlation visually (Figure 3). We calculated the aver-
age increase from the basal line for each cytokine and
chemokine in the IAV-infected models and presented
them on charts with a logarithmic axis. On evaluation,
we noted that BALF was obtained using PBS. Therefore,
relative values rather than absolute values (i.e., shape sim-
ilarity among radar charts) were important in evaluating
the correlation between proﬁles, especially when compar-
ing the proﬁle of BALF.
Although the serum cytokine/chemokine proﬁles showed
a considerable degree of similarity between both the pneu-
monia and encephalitis models (Figure 3(a)), the local
cytokine/chemokine responses diﬀered between BALF
and CSF (Figure 3(b)). In the pneumonia model, the pro-
ﬁles were similar between serum and BALF, but some
deviations were identiﬁed: a larger shift to the lower side
in the serum chart and a larger shift to left side in the
BALF chart (Figure 3(c)). In the encephalitis model, a
low level of similarity between the proﬁles for serum and
CSF was detected, with the CSF chart showing a larger
overall increase than the serum chart (Figure 3(d)).
4. Discussion
Cytokines and chemokines contribute to the overall pathol-
ogy of IAV infection. This study investigated the cytokine/
chemokine proﬁles associated with diﬀerent diseases induced
by IAV. Inﬂuenza A/WSN/33 (H1N1) virus, which has the
ability to infect multiple organs, was used throughout this
study to avoid disparities between IAV strains. We generated
pneumonia and encephalitis mouse models by intranasal and
intracranial inoculation with a lethal dose of IAV, respec-
tively, to investigate the eﬀects of infection site on cytokine/
chemokine proﬁles. Results revealed no detectable virus in
the brain in the pneumonia model or in the lung in the
encephalitis model.
As a result of IAV infection, the concentrations of almost
all examined cytokines and chemokines were signiﬁcantly
increased both in serum and in local samples (BALF or
CSF) from the site of infection. Several reports of clinical
studies have described systemic and local levels of cytokines
and chemokines in patients with IAV infection of various
types [8–11], but data related to the correlation between
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Figure 2: Concentrations of 12 cytokines/chemokines in serum and local samples from pneumonia and encephalitis models. Serum
concentrations of cytokines/chemokines in the pneumonia model (a) and the encephalitis model (b). Local concentrations of cytokines/
chemokines in the BALF in the pneumonia model (c) and the CSF in the encephalitis model (d). Levels of 12 cytokines/chemokines were
measured using a multiplex bead-based assay. Data represent the mean± SEM values. All samples showed a signiﬁcant increase in
cytokine/chemokine levels for the IAV-infected groups, with the exception of serum IL-1β (∗) in the encephalitis model (n = 6 per group).
Statistical comparisons were conducted using the Mann–Whitney U test.
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diﬀerent types of diseases (e.g., pneumonia versus encephali-
tis) or samples (e.g., serum versus BALF) are scarce. In this
study, we found the cytokine/chemokine proﬁles in serum
and local samples (BALF in pneumonia or CSF in encephali-
tis) to compare the systemic and local immune responses
both in pneumonia and in encephalitis models induced by
IAV infection.
This study revealed visually, with radar charts, that the
local cytokine/chemokine proﬁles diﬀered depending on the
infection site, although the serum proﬁles were similar. The
shift to the lower area in the radar chart for CSF
contributed to the diﬀerence between local cytokine/chemo-
kine proﬁles. This ﬁnding indicated the more predominance
of Th2 cytokines (IL-10, IL-13) in CSF than in BALF
following IAV infection. These cytokines are classiﬁed as
anti-inﬂammatory cytokines, which are fundamentally
important for ameliorating inﬂammatory response and
thereby preventing excessive host damage. Earlier reports
described that IL-13 induces cell death of activated microglia,
which is important for the prevention of chronic inﬂamma-
tion [16]. Elevated IL-10 concentrations in CSF are also
reportedly associated with mild encephalitis/encephalopathy
during IAV infection with a reversible splenial lesion with a
good clinical course, which indicates that IL-10 might work
to localize the lesion and to prevent sequelae [17]. Puntambe-
kar et al. recently reported that IL-10 limited the expansion of
CNS damage following viral-induced demyelination [18].
These unique ﬁndings related to the local immune response
in the brain might be associated with characteristics of
immune privilege [19]. However, further studies must be
conducted to elucidate the cytokine/chemokine production
mechanism.
Another key ﬁnding of this study was that the cytokine/
chemokine proﬁles diﬀered between serum and local samples
(BALF or CSF) for the pneumonia and encephalitis models.
Several reports have made speciﬁc mention of the diﬀerence
of cytokine proﬁles between systemic and local samples in
case series of inﬂuenza virus infection [9, 11, 20–24]. Some
of them further presented the conclusion that the local sam-
ples are superior to serum samples for evaluating disease
severity (Tables 1 and 2). These ﬁndings support our view
of the importance of investigating local immune responses
in IAV pathology.
Evaluating blood samples alone might be insuﬃcient to
understand the local immune reactions at the primary infec-
tion site. Therefore, using local samples from the infection
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Figure 3: Comparison of cytokine/chemokine proﬁles as shown by radar charts. Average increase from the basal line of each cytokine/
chemokine is shown on a chart with a logarithmic axis. Proinﬂammatory cytokines (right side of charts), anti-inﬂammatory cytokines
(lower side of charts), and chemokines (left side of charts) are highlighted in pink, yellow, and blue, respectively: P-serum, serum from
pneumonia model; E-serum, serum from encephalitis model; BALF, bronchoalveolar lavage ﬂuid from pneumonia model; and CSF,
cerebrospinal ﬂuid from encephalitis model.
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site might be highly beneﬁcial for elucidation of the clinical
pathology of a particular patient and for devising an eﬀective
treatment plan. The reasons for discrepancies in cytokine
and chemokine levels among sera and local samples were
not explored in this study, but the topic might form the basis
for further investigation of the innate immune responses
during severe inﬂuenza virus infection (such as pneumonia
and encephalitis) and therapeutic approaches. Whether spe-
ciﬁc cytokine and chemokine inhibitors have potential for
severe inﬂuenza virus infection should be evaluated in future
studies using appropriate experimental models.
5. Conclusion
In conclusion, local immune responses against IAV infection
appear to vary depending on the infection site, whereas
systemic immune responses remain almost similar. In addi-
tion, the cytokine and chemokine proﬁles in local immune
responses might diﬀer from those of systemic immune
responses. Local samples such as CSF or BALF, which reﬂect
the infection site pathology, are important for evaluating
local immune responses and for aiding clinicians in devising
the most appropriate treatment strategies.
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